TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05108272

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microneedling
Description: Derma Pen is an electric device, used for microneedling. Derma pen has a Cartridge which has microneedles fitted. These needles penetrate the skin upto 2mm

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Collagen Induction
Description: It is self-adhesive sheet made from medical graded Silicone. It has micropore technology which entraps moisture where it is needed on scared skin.
Study: NCT05865340

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: oral health + MED diet
Description: oral health + MED diet education

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: oral health
Description: oral health education

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: MED diet
Description: MED diet education
Study: NCT05742165

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time Restricted Eating (TRE)
Description: TRE involves only consuming food and beverages during a particular consecutive time period - in the case of this study, either 6 hours or 10 hours. Participants will self-select the timing of their first eating occasion of the day, with the provision that their first meal of the day will be consumed within 3 hours of their wake- up time and finished no less than 3 hours prior to bed time. During the fasting period, participants will be encouraged to drink water, and will be permitted to consume zero-calorie beverages. Participants will be instructed to self-monitor all eating occasions using the MyCircadianClock (mCC) smartphone app, which date- and time-stamps all food entries. Participants will also be instructed to self-monitor their body weight daily using a Bluetooth-enabled Renpho scale, which permits remote collection of body weight.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time Restricted Eating (TRE)
Description: TRE involves only consuming food and beverages during a particular consecutive time period - in the case of this study, either 6 hours or 10 hours. Participants will self-select the timing of their first eating occasion of the day, with the provision that their first meal of the day will be consumed within 3 hours of their wake- up time and finished no less than 3 hours prior to bed time. During the fasting period, participants will be encouraged to drink water, and will be permitted to consume zero-calorie beverages. Participants will be instructed to self-monitor all eating occasions using the MyCircadianClock (mCC) smartphone app, which date- and time-stamps all food entries. Participants will also be instructed to self-monitor their body weight daily using a Bluetooth-enabled Renpho scale, which permits remote collection of body weight.
Study: NCT05325294

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MiniMed 780G System
Description: MiniMed™ 780G Insulin Pump, Guardian™ 4 Glucose Sensor, and Guardian 4 Transmitter; used with Insulin Lyumjev® insulin lispro-aabc
Study: NCT05496491

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Neoadjuvant Chemoradiotherapy
Description: 5-week neoadjuvant radiotherapy regimen (28 x 1.8 Gy) combined with Capecitabine (bid 800 mg/m2, twice daily, on days 1-33-38)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Chemoradiotherapy
Description: 5-week neoadjuvant radiotherapy regimen (28 x 1.8 Gy) combined with Capecitabine (bid 800 mg/m2, twice daily, on days 1-33-38)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant Chemotherapy
Description: 8 cycles of CAPOX (Capecitabine bid 1000 mg/m2, twice daily, day 1-14, every 3 weeks and Oxaliplatin 130 mg/m2, day 1, every 3 weeks) or alternatively, 12 cycles of folinate, fluorouracil and oxaliplatin (FOLFOX)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Consolidation Chemotherapy
Description: CAPOX (Capecitabine bid1000 mg/m2 and Oxaliplatin 130 mg/m2, day 1, every 3 weeks) or alternatively FOLFOX
Study: NCT04917042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: Subjects will receive 520 mg/m2/dose (subjects 12-17 years old) or 800 mg of tazemetostat orally twice daily in 28 day cycles. Subjects will receive treatment with tazemetostat up to 2 years or until disease progression or unacceptable toxicity occurs.
Study: NCT05504278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI351
Description: recommended dose, po

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI351
Description: recommended dose, po
Study: NCT06197269

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short duration antibiotics
Description: antibiotic therapy will be stopped at the time of randomization i.e. 72 hrs after starting treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard duration antibiotics
Description: Antibiotics will be continued for 5-7 days more, 72 hrs after starting treatment.
Study: NCT06247371

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision aid
Description: The Singapore developed HF DA is a A3 sized one-page poster designed to convey information about HF medications options (ACEI and ARNI only) and their pros and cons. The DA contains informative attributes of both medications that are presented side by side for comparison. These attributes include subsidized cost, frequency of use, duration of use, route of administration, low blood pressure side effect rate and benefits such as non-hospitalization rate and survival rate.
Study: NCT05504278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI351
Description: recommended dose, po

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: 500mg/m\^2, Q2W, day1, i.v.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 500mg/m\^2, Q3W, day1, i.v.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 500mg/m\^2, Q3W, day1, i.v.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC=5, Q3W, day1, i.v.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC=5, Q3W, day1, i.v.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: 200mg, Q3W, day1, i.v.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cis-platinum
Description: 75mg/m\^2, Q3W, day1, i.v.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cis-platinum
Description: 75mg/m\^2, Q3W, day1, i.v.
Study: NCT05658848

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collaborative infertility counseling
Description: Collaborative infertility counseling for coping stratigies and marital satisfaction
Study: NCT06777368

Intervention type: DEVICE
Intervention: Medtronic TAV
Description: Medtronic TAV where commercially available

Intervention type: DEVICE
Intervention: Edwards TAV
Description: Edwards TAV where commercially available.
Study: NCT06767787

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic sleeve gastrectomy
Description: Participants undergoing laparoscopic sleeve gastrectomy (LSG) will be clinically assessed and provided consent to this procedure by one of the bariatric surgeons affiliated with the bariatric surgery program. LSG will be performed at a local tertiary care hospital as either a day procedure or as an overnight stay if medically indicated. Patients will be discharged once they can tolerate a liquid diet. Patients will then attend regular follow-ups with their surgeons and the bariatric surgery program, in accordance with a standardized clinical pathway protocol.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic sleeve gastrectomy
Description: Participants undergoing laparoscopic sleeve gastrectomy (LSG) will be clinically assessed and provided consent to this procedure by one of the bariatric surgeons affiliated with the bariatric surgery program. LSG will be performed at a local tertiary care hospital as either a day procedure or as an overnight stay if medically indicated. Patients will be discharged once they can tolerate a liquid diet. Patients will then attend regular follow-ups with their surgeons and the bariatric surgery program, in accordance with a standardized clinical pathway protocol.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: total knee arthroplasty
Description: Patients undergoing unilateral total knee arthroplasty (TKA) will be clinically assessed and provided consent to their procedure by an orthopaedic surgeon trained in joint arthroplasty. TKA will be performed at a local tertiary care hospital as either a day procedure or as an overnight stay if medically indicated. Patients will be discharged once physiotherapy clears them. Patients will attend regular follow-ups with their surgeon in accordance with a standardized clinical pathway protocol.
Study: NCT00995397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexchlorpheniramine 1% lotion
Description: Small amount applied over the lesion twice a day for 7 days.
Study: NCT06767787

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: total knee arthroplasty
Description: Patients undergoing unilateral total knee arthroplasty (TKA) will be clinically assessed and provided consent to their procedure by an orthopaedic surgeon trained in joint arthroplasty. TKA will be performed at a local tertiary care hospital as either a day procedure or as an overnight stay if medically indicated. Patients will be discharged once physiotherapy clears them. Patients will attend regular follow-ups with their surgeon in accordance with a standardized clinical pathway protocol.
Study: NCT06765096

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Virtual Reality Model
Description: Participants will receive one session on educational virtual reality (VR) model for pelvic floor anatomy.
Study: NCT06771791

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: oral provocation test
Description: Progressively increasing doses of peeled fresh Golden apple or placebo will be consumed by the patient (4g, 12g, 40g, 120g) with a time interval of 20 minutes between each dose.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oral provocation test
Description: Progressively increasing doses of peeled fresh Golden apple or placebo will be consumed by the patient (4g, 12g, 40g, 120g) with a time interval of 20 minutes between each dose.
Study: NCT06580275

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CLAAS
Description: All eligible subjects will have an LAA closure attempt using the CLAAS device guided by ICE technology.
Study: NCT06759844

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Booklet
Description: A printed booklet containing general information on chronic disease management provided to participants for reference without interactive or digital features

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Health Application
Description: A mobile health application that facilitates self-management of chronic conditions through daily education, personalized goal setting, and lifestyle monitoring. The intervention aims to improve participants' health behaviors and clinical outcomes by promoting active engagement with their health.
Study: NCT06778629

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transversalis Fascia Plane Block
Description: After the wound closure is completed and the patient is still under general anesthesia the TFPB will be performed. As the patient is in the supine position, the high-frequency linear US probe (11-12 MHz, Vivid Q) and a 22-G 80-mm needle (Stimuplex® Ultra 360®, Braun, USA) will be placed longitudinally, 2-3 cm laterally, just above the iliac crest at the mid-axillary line. After the external oblique, internal oblique, and transversus abdominis muscles are distinguished, the common aponeurosis of the transversus abdominis and the internal oblique muscle will be found. The block needle will be directed from anterior to posterior, using an in-plane technique, the block needle will be advanced and the block location will be confirmed by injecting 5 ml of saline. Once the block location is confirmed, 30 ml of 0.25% bupivacaine (Buvicaine, Polifarma ®) will be applied between the transversus abdominis muscle and transversalis fascia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Post Operative Pain Management
Description: Acetaminophen 1 gr (Paracerol, Polifarma®) intravenous (IV), and tramadol (Contramal, Abdi İbrahim®) 100 mg IV will be administered to all patients 30 minutes before wound closure. After surgery, Acetaminophen (Paracerol, Polifarma®) 1 gr IV, and tramadol (Contramal, Abdi İbrahim®) 100 mg IV will be given three times a day. Another anesthesiologist will assess patients after surgery. If the patient's pain score (NRS) is 4 or higher, IV pethidine (Aldolan, Liba Laboratory ®) 0,5 mg/kg will be given as a rescue analgesic.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Post Operative Pain Management
Description: Acetaminophen 1 gr (Paracerol, Polifarma®) intravenous (IV), and tramadol (Contramal, Abdi İbrahim®) 100 mg IV will be administered to all patients 30 minutes before wound closure. After surgery, Acetaminophen (Paracerol, Polifarma®) 1 gr IV, and tramadol (Contramal, Abdi İbrahim®) 100 mg IV will be given three times a day. Another anesthesiologist will assess patients after surgery. If the patient's pain score (NRS) is 4 or higher, IV pethidine (Aldolan, Liba Laboratory ®) 0,5 mg/kg will be given as a rescue analgesic.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Port Site Infiltration
Description: A total of 20 ml of 0.25% bupivacaine ( (Buvicaine, Polifarma ®) will be applied to the trocar entry points by the surgeon at the beginning of the operation, before entering the trocars.
Study: NCT00995397

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexchlorpheniramine 1% cream
Description: Small amount applied over the lesion twice a day for 7 days.
Study: NCT06778629

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Port Site Infiltration
Description: A total of 20 ml of 0.25% bupivacaine ( (Buvicaine, Polifarma ®) will be applied to the trocar entry points by the surgeon at the beginning of the operation, before entering the trocars.
Study: NCT06778044

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ReDirection 1.0
Description: A free, anonymous, online, self-guided cognitive behavioral therapy (CBT) intervention. Consists of 6 modules.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ReDirection 2.0
Description: A free, anonymous, online, self-guided, cognitive behavioural therapy (CBT) intervention. Consists of 5 modules and the option for asynchronous messaging with a ReDirection specialist.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Waitlist
Description: Participants in the waitlist control will wait six weeks before starting active treatment. While on the waitlist, participants will respond to questions about ongoing sexual urges and behaviour.
Study: NCT06778213

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: NovoHelisen Depot
Description: allergen immunotherapy treatment for 12 months with house dust mite allergen preparation

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NovoHelisen Depot
Description: allergen immunotherapy treatment for 12 months with house dust mite allergen preparation
Study: NCT06778421

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intramuscular injection
Description: Injection performed using method for aesthetic facial rejuvenation procedure with neuromuscular chemodenervation agents

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Intramuscular injection
Description: Injection performed using method for aesthetic facial rejuvenation procedure with neuromuscular chemodenervation agents

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (Botox®) Injections
Description: Injection of 64 units of active drug at a ratio of 4 units to 0.1 mL of sterile, preservative-free 0.9% Sodium Chloride Injection, United States Pharmacopeia (USP) Only~- Abbvie/Allergan drug.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride
Description: Placebo injection of the same volume of preservative-free 0.9% Sodium Chloride Injection, United States Pharmacopeia (USP) Only.
Study: NCT05825430

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Direct pecs block
Description: Patients will receive direct PECS block by surgeon after closure of pectoralis muscle under direct vision and before skin closure.~All patients will receive the same general anaesthetic technique: In the form of iv induction by propofol 2mg /kg ,fentanyl 2 mic/ kg and intubation will be facilitated by atracurium 0.5 mg/kg. Anaesthesia will be maintained by isoflurane 1.5 MAC and incremental doses of atracurium 0.15 mg/kg every 20 min. At the end of surgery neuromuscular blocker reversed by neostigmine 50 micg/kg + atropine 20 micg /kg i.v.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound guided pecs block
Description: Patients will receive ultrasound guided pecs block after induction and before skin incision.~All patients will receive the same general anaesthetic technique: In the form of iv induction by propofol 2mg /kg ,fentanyl 2 mic/ kg and intubation will be facilitated by atracurium 0.5 mg/kg. Anaesthesia will be maintained by isoflurane 1.5 MAC and incremental doses of atracurium 0.15 mg/kg every 20 min. At the end of surgery neuromuscular blocker reversed by neostigmine 50 micg/kg + atropine 20 micg /kg i.v.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: general anaesthetic technique only
Description: All patients will receive the same general anaesthetic technique: In the form of iv induction by propofol 2mg /kg ,fentanyl 2 mic/ kg and intubation will be facilitated by atracurium 0.5 mg/kg. Anaesthesia will be maintained by isoflurane 1.5 MAC and incremental doses of atracurium 0.15 mg/kg every 20 min. At the end of surgery neuromuscular blocker reversed by neostigmine 50 micg/kg + atropine 20 micg /kg i.v.
Study: NCT05771636

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mental Imagery
Description: Mental Imagery consists of imagining a situation in the most vivid way possible, including all sensory modalities (visual image, sensations, smells, sounds, emotions). It can be used to act as a motivational amplifier, by pre-experimenting a situation in imagination.~The best possible self imagery consists of imagining the best version possible of one's self , after accomplishing all their major life goals, in a future where everything turned out the best way possible. What does this best version of you do, in terms of actions, on an everyday basis ? The planned imagery exercise consists of rehearsing an activity in a mental way, before actually doing it. It can help to visualize the outcome of this activity and benefits it can provide to the participant before actually getting it done.
Study: NCT06777316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CGT4859
Description: CGT4859 is a selective FGFR2/3 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CGT4859
Description: CGT4859 is a selective FGFR2/3 inhibitor
Study: NCT05738161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magrolimab
Description: Magrolimab in combination with cytotoxic chemotherapy in advanced urothelial carcinoma
Study: NCT06765317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glofitamab
Description: C1D8 2.5 mg iv; C1D15 10 mg iv; C2D1-onwards: 30 mg iv, every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab
Description: 1.8 mg/kg iv C1D1 onwards, every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 iv D1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 400 mg/m2 iv D1
Study: NCT05738161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Standard first line platinum-based chemotherapy in advanced urothelial carcinoma

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Standard first line platinum-based chemotherapy in advanced urothelial carcinoma
Study: NCT06765317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 25 mg/m2 iv D1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab:
Description: 1000 mg iv C1D1 (7 days prior to glofitamab administration) single dose
Study: NCT06771076

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cream with CBD and natural ingredients
Description: Topical application of the cream with CBD and natural ingredients on the injured areas, twice per day (after waking up, and before going to bed). A crossover with the other intervention will be done in the next/previous month (depending on the arm).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cream with CBD and natural ingredients
Description: Topical application of the cream with CBD and natural ingredients on the injured areas, twice per day (after waking up, and before going to bed). A crossover with the other intervention will be done in the next/previous month (depending on the arm).
Study: NCT05989126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aflibercept 8 mg PFS
Description: Sterile aqueous solution in a single-dose PFS administered by intravitreal (IVT) injection
Study: NCT05087784

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Technology supported, coordinated survivorship care using wearable devices, supportive patient-apps and cardio-oncology physician apps
Description: Patient-centered, technology-supported integrated survivorship- and care management
Study: NCT05205746

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant NDV Vectored Vaccine for SARS-CoV-2
Description: Recombinant Newcastle Disease Virus Vectored Vaccine for SARS-CoV-2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant NDV Vectored Vaccine for SARS-CoV-2
Description: Recombinant Newcastle Disease Virus Vectored Vaccine for SARS-CoV-2

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Placebo
Description: Physiological saline solution of Sodium Chloride at 0.9% After mask opening ChAdOx-1-S\[recombinant\]) Intramuscular

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Placebo
Description: Physiological saline solution of Sodium Chloride at 0.9% After mask opening ChAdOx-1-S\[recombinant\]) Intramuscular
Study: NCT06462807

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ARC
Description: ARC is an evidence-based intervention that uses three strategies (ARC principles, ARC component tools, and ARC mental models) to create organizational social contexts (OSCs) that support the implementation of interventions to improve patient outcomes.